Surgery following neoadjuvant chemotherapy for non‑small‑cell lung cancer patients with unexpected persistent pathological N2 disease

Hu,Xue‑Fei; Duan,Liang; Jiang,Ge‑Ning; Chen,Chang; Fei,Ke

doi:10.3892/mco.2015.706

Surgery following neoadjuvant chemotherapy for non‑small‑cell lung cancer patients with unexpected persistent pathological N2 disease

Authors:
- Xue‑Fei Hu
- Liang Duan
- Ge‑Ning Jiang
- Chang Chen
- Ke Fei
View Affiliations

Affiliations: Department of General Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, P.R. China
Published online on: December 11, 2015 https://doi.org/10.3892/mco.2015.706
Pages: 261-267

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with mediastinal lymph node (LN) downstaging following neoadjuvant chemotherapy exhibit improved outcomes compared with patients with persistent N2 disease. The aim of this study was to compare clinicopathological characteristics and survival between patients with unexpected and expected persistent N2 disease following surgery for non‑small‑cell lung cancer (NSCLC). This retrospective analysis included 348 patients with NSCLC who underwent surgery following chemotherapy at the Shanghai Pulmonary Hospital, Tongji University School of Medicine, between 1995 and 2012. According to the results of the imaging examinations and postoperative pathology, the patients were divided into three groups, namely groups I (nodal downstaging, pN0‑1), II (expected persistent N2 disease) and III (unexpected persistent N2 disease). The rates of overall survival (OS) and disease‑free survival (DFS) were estimated by the Kaplan‑Meier method. Univariate and multivariate analyses were performed to identify the independent risk factors for OS and DFS. The mortality rate was 1.1% during the postoperative period. Perioperative complications occurred in 45 patients (12.9%). The 5‑year OS rate was 32.2, 6.3 and 25.9% in groups I, II and III, respectively (group I vs. III, p=0.023; and group III vs. II, p<0.001). The 5‑year DFS rate was 30.1, 5.1 and 22.4% in groups I, II and III, respectively (group I vs. III, p=0.012; and group III vs. II, p<0.001). Grouping, predicted forced expiratory volume in 1 sec, N downstaging and skip N2 metastasis were identified as independent predictive factors associated with OS, whereas the independent risk factors associated with DFS were grouping and N downstaging. Patients with unexpected persistent N2 disease exhibited better survival compared with those with expected persistent N2 disease. Surgery following chemotherapy remains the optimal approach for a proportion of patients with persistent N2 disease.

View Figures

View References

1	Groome PA, Bolejack V, Crowley JJ, et al: The IASLC Lung Cancer Staging Project: validation of the proposals for the revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2:694–705. 2007. View Article : Google Scholar : PubMed/NCBI
2	Martini N and Flehinger BJ: The role of surgery in N2 lung cancer. Surg Clin North Am. 67:1037–1049. 1987.PubMed/NCBI
3	Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V and Le Chevalier T: Survival of patients with resected N2 non-small-cell lung cancer. Evidence for a subclassification and implications. J Clin Oncol. 18:2981–2989. 2000.PubMed/NCBI
4	Albain KS, Rusch VW, Crowley JJ, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 13:1880–1892. 1995.PubMed/NCBI
5	Martini N, Kris MG, Flehinger BJ, et al: Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering experience with 136 patients. Ann Thorac Surg. 55:1365–1373; discussion 1373–1374. 1993. View Article : Google Scholar
6	Lorent N, De Leyn P, Lievens Y, Verbeken E, Nackaerts K, Dooms C, Van Raemdonck D, Anrys B and Vansteenkiste J: Leuven Lung Cancer Group: Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: Analysis of a 7-year prospective experience. Ann Oncol. 15:1645–1653. 2004. View Article : Google Scholar : PubMed/NCBI
7	Rosell R, Gómez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 330:153–158. 1994. View Article : Google Scholar : PubMed/NCBI
8	Pataer A, Kalhor N, Correa AM, et al: University of Texas M. Histopathology. J Thorac Oncol. 7:825–832. 2012. View Article : Google Scholar : PubMed/NCBI
9	Betticher DC, Schmitz Hsu SF, Tötsch M, et al: Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 21:1752–1759. 2003. View Article : Google Scholar : PubMed/NCBI
10	Kim YN, Yi CA, Lee KS, et al: A proposal for combined MRI and PET/CT interpretation criteria for preoperative nodal staging in non-small-cell lung cancer. Eur Radiol. 22:1537–1546. 2012. View Article : Google Scholar : PubMed/NCBI
11	Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
12	Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer. 47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
13	Naruke T, Suemasu K and Ishikawa S: Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg. 76:832–839. 1978.PubMed/NCBI
14	Pass HI, Pogrebniak HW, Steinberg SM, Mulshine J and Minna J: Randomized trial of neoadjuvant therapy for lung cancer, Interim analysis. Ann Thorac Surg. 53:992–998. 1992. View Article : Google Scholar : PubMed/NCBI
15	Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 86:673–680. 1994. View Article : Google Scholar : PubMed/NCBI
16	Depierre A, Milleron B, Moro-Sibilot D, et al: French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 20:247–253. 2002. View Article : Google Scholar : PubMed/NCBI
17	Nagai K, Tsuchiya R, Mori T, Tada H, Ichinose Y, Koike T and Kato H: Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg. 125:254–260. 2003. View Article : Google Scholar : PubMed/NCBI
18	van Meerbeeck JP, Kramer GW, Van Schil PE, et al: European Organisation for Research and Treatment of Cancer-Lung Cancer Group: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 99:442–450. 2007. View Article : Google Scholar : PubMed/NCBI
19	Silvestri GA, Gould MK, Margolis ML, et al: Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 132((Suppl 3)): 178S–201S. 2007. View Article : Google Scholar : PubMed/NCBI
20	Kim HK, Choi YS, Kim K, Shim YM, Park K, Ahn YC, Lee KS, Choi JY and Kim J: Outcomes of mediastinoscopy and surgery with or without neoadjuvant therapy in patients with non-small cell lung cancer who are N2 negative on positron emission tomography and computed tomography. J Thorac Oncol. 6:336–342. 2011. View Article : Google Scholar : PubMed/NCBI
21	Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E and Young V: Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg. 33:104–109. 2008. View Article : Google Scholar : PubMed/NCBI
22	Eberhardt W, Wilke H, Stamatis G, et al: Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol. 16:622–634. 1998.PubMed/NCBI
23	Port JL, Korst RJ, Lee PC, et al: Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg. 79:1686–1690. 2005. View Article : Google Scholar : PubMed/NCBI